Correlation of CD33 with poorer prognosis in childhood ALL implicates a potential of anti-CD33 frontline therapy
2005
Abstract
We evaluated the prognostic impact of MyAgs in uniformly treated patients. From 9/1996 to 10/2002, 343 children with ALL were enrolled in a Czech nationwide study ALL-BFM95.
In 327 patients (96%) immunophenotyping and molecular genetics were performed centrally in our reference labs. Prednisone good responders (PGR) with WBC at diagnosis <20000/μL and age 1-5 years were assigned into standard risk group (SRG).
High RG (HRG) corresponded to prednisone poor response (PPR) or no remission at day 33 or BCR/ABL or MLL/AF4 fusions. The remaining patients were in the intermediate RG (IRG).
Full statistics details are in the Supplementary Information.